摘要
目的深入探析在临床治疗尿毒症患者中应用高通量血液透析的临床应用成效。方法随机筛选于2017年1月至2018年1月入院接受诊治的66例尿毒症患者,根据病床单双号分为治疗组(n=30)施以高通量血液透析治疗,对照组(n=36)施以常规低通量血液透析治疗。将两组的BUN、SCr、β2-MG、PTH、Hb、HCT指标水平、并发症发生情况进行分析与比较。结果 (1)两组的检测指标水平变化情况:两组在治疗前的BUN、SCr、β2-MG、PTH指标水平比较差异不存在统计学意义(P>0.05);经治疗,治疗组的BUN、SCr、β2-MG、PTH指标水平均低于对照组,差异较大(P<0.05),存在统计学意义;(2)两组的Hb、HCT水平情况:两组在治疗前的Hb、HCT指标水平比较差异不存在统计学意义(P>0.05);相比于对照组,治疗组的Hb、HCT指标水平得到明显提升,差异较大(P<0.05),存在统计学意义;(3)两组的并发症情况:相比于对照组,治疗组的并发症得到明显减少,差异较大(P<0.05),存在统计学意义。结论在临床治疗尿毒症患者中应用高通量血液透析,施行疗效更为可观,并发症少,是一种治疗尿毒症患者的安全有效方法,医疗价值高。
Objective To investigate the clinical application of high-flux hemodialysis in clinical treatment of uremic patients. Methods Randomly selected 66 patients with uremia who were admitted to hospital from January 2017 to January 2018. The treatment group(n =30) was treated with high flux hemodialysis and the control group(n =36) was treated with conventional low flux hemodialysis. The two groups of BUN, SCr, β2-MG, PTH, Hb, HCT levels and complications were analyzed and compared. Results(1) Changes in the detection index of the 2 groups: There was no significant difference in the levels of BUN, SCr, β2-MG and PTH before treatment in the 2 groups(P〉0.05); after treatment, the treatment group The levels of BUN, SCr, β2-MG, and PTH were significantly lower than those in the control group(P〈0.05), and there were statistical significance;(2) The levels of Hb and HCT in the 2 groups: Hb before treatment in the 2 groups. There was no significant difference in the level of HCT between the two groups(P〉 0.05). Compared with the control group, the Hb and HCT levels of the treatment group were significantly higher(P〈 0.05), and there was statistical significance;(3) Complications of the 2 groups: Compared with the control group, the complications of the treatment group were significantly reduced(P〈0.05), and there was statistical significance. Conclusion The application of high-throughput hemodialysis in clinical treatment of uremic patients is more effective and less complications. It is a safe and effective method for the treatment of uremic patients, and has high medical value.
作者
曹瑞民
王诺敏
CAO Rui-min;WANG Nuo-min(Hure Banner Hospital,Tongliao,Inner Mongolia,02820)
出处
《智慧健康》
2018年第19期55-56,59,共3页
Smart Healthcare